Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 7/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | DPP4 | P27487 | 5/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CPT2 | P23786 | 1/20 | 0.33 |
| ▸ | CPT1A | P50416 | 1/20 | 0.33 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23418851 | 0.76 | EPHX2 (0.63) | EPHX2 | |
| SCHEMBL23419215 | 0.76 | EPHX2 (0.63) | EPHX2 | |
| SCHEMBL23389123 | 0.73 | EPHX2 (0.46) | EPHX2DPP4DPP7KCNH2 | |
| SCHEMBL23389124 | 0.73 | EPHX2 (0.46) | EPHX2DPP4DPP7KCNH2 | |
| SCHEMBL25993358 | 0.72 | GFER (0.39) | BTKEPHX2GAA | |
| SCHEMBL23389099 | 0.71 | KDM2B (0.41) | BTKEPHX2 | |
| SCHEMBL23389098 | 0.71 | KDM2B (0.41) | BTKEPHX2 | |
| SCHEMBL25991605 | 0.68 | EPHX2 (0.53) | EPHX2GAA | |
| SCHEMBL23389188 | 0.68 | KMT2A (0.52) | EPHX2 | |
| SCHEMBL23419111 | 0.68 | KMT2A (0.52) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | CASP6, CASP1, CASP10 | BTK 3023/4885EPHX2 3551/4885DPP4 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.